Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer pain in outpatients with:~* Opioid based therapy due to pain~* Breakthrough pain or~* Extreme pain on movement~* Age \>= 18 years~Exclusion Criteria:~* Patients unable to give written informed consent~* Patients unable to understand how to handle and document the use of the study medication~* Known drug allergies or intolerance to ketamine~* Known drug allergies or intolerance to morphine~* Known allergy to crustacea or chitosan~* Patients using snuff at a regular basis~* Recreational drug addiction or abuse~* Serious intranasal or epipharyngeal Problems (Septum wall defects, cancer)~* Mental/psychiatric disorder~* Patients with renal failure (clearance \< 30 ml/min)~* Pregnancy and breast feeding mothers~* Patients not understanding German~* Patient having arterial hypertonia with measured values \> 180/95

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- morphine drops solo and placebo spray (Type: OTHER): morphine 2% drops~1. daily fixed dose of morphine equivalents \< 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~2. daily fixed dose of morphine equivalents =/\> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards
- ketamine/chitosan spray nasal and placebo drops (Type: OTHER): 5 mg ketamine all 5 minutes, maximal 4 times an hour
- morphine drops and ketamine/chitosan spray nasal (Type: OTHER): see above

Based on this trial design, predict the completion outcome and termination type (if applicable).